Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Mitsune Tanimoto,Koichi Miyamura,Toshihiro Miyamoto,Kazuhito Yamamoto,Masafumi Taniwaki,Shinya Kimura,Kazuma Ohyashiki,Tatsuya Kawaguchi,Itaru Matsumura,Tomoko Hata,Hisashi Tsurumi,Shigeki Saito,Masayuki Hino,Seiji Tadokoro,Kuniaki Meguro, Hideo Hyodo,Masahide Yamamoto,Kohmei Kubo,Junichi Tsukada,Midori Kondo

Blood（2014）

引用 0|浏览1

暂无评分

摘要

Background: Nilotinib elicits faster, deeper molecular responses than imatinib as frontline treatment for CML-CP and is also approved as second-line treatment for patients (pts) intolerant of or resistant to imatinib.However, the optimal management of pts with SoR to frontline imatinib treatment has not been determined. Here, we present final data from the Study to Evaluate Nilotinib in CML pts with SubOptimal Response (SENSOR, NCT0104387), in which adult pts with molecular SoR to frontline imatinib switched to nilotinib.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要